A World Without
Infectious Disease
Update on Vir’s Response to the Omicron COVID-19 Variant
Vir and partner GSK have announced new preclinical data demonstrating that our investigational COVID-19 monoclonal antibody retains activity against the full combination of mutations in the spike protein of the new Omicron SARS-CoV-2 variant. Read more here.
Global Impact
Infectious diseases are among the leading causes of death worldwide.
Vir is focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases.
A new era
Remarkable advances have improved our understanding of pathogens and the immune system.
Our four current technology platforms are designed to, either individually or in combination, stimulate and enhance the immune system by exploiting critical observations of natural immune processes.
To prevent, treat, and cure
We are taking aim at some of the world’s largest and most serious infectious diseases, infections that are evasive, challenging, or insufficiently addressed by current approaches including COVID-19, hepatitis B, influenza A and HIV.
